Health Trials

About this trial

In this study the investigators would like to investigate the degree of damage of the synapses, an important part of the neurons vital for the communications between neurons, in Multiple System Atrophy (MSA), and pathology related to abnormal accumulation of a protein named tau, in Progressive Supranuclear Palsy (PSP).

Eligibility criteria

Qualifiers

Combined (estrogen and progesterone containing) hormonal contraception associated with initiation of ovulation( oral, intravaginal, or transdermal);

Progesterone-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable);

Intrauterine device;

Intrauterine hormone releasing system;

Disqualifiers

Any spinal malformation or other aspects (e.g. tattoos) / clinical findings (e.g. papilledema) that may complicate or contraindicate lumbar puncture, as judged by the investigator.

Neoplasm or other space-occupying intracranial lesion on MRI. Any clinically important abnormality, as determined by the investigator, on physical examination or vital signs, ECG, or clinical laboratory test results other than abnormality due to a stable, well-controlled medical condition; or any abnormality that could be detrimental to the subject or could compromise the study.

Trial design

Treatments tested in this trial

  • Study procedures for MSA patients
  • Study procedures for PSP patients

Treatment groups

36 Participants
are divided into 2 treatment groups

Locations

1
University of ExeterSE16 7RJ, Exeter United Kingdom

Sponsors and collaborators

University of Exeter

Lead sponsor

Source ClinicalTrials.gov